RIVA RIVAROXABAN TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

RIVAROXABAN

Disponible desde:

LABORATOIRE RIVA INC.

Código ATC:

B01AF01

Designación común internacional (DCI):

RIVAROXABAN

Dosis:

10MG

formulario farmacéutico:

TABLET

Composición:

RIVAROXABAN 10MG

Vía de administración:

ORAL

Unidades en paquete:

15G/50G

tipo de receta:

Prescription

Resumen del producto:

Active ingredient group (AIG) number: 0152487001; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2023-11-01

Ficha técnica

_Page 1 of 111_
_RIVA RIVAROXABAN (rivaroxaban)_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
RIVA RIVAROXABAN
Rivaroxaban Tablets
Tablets, 2.5 mg, 10 mg, 15 mg and 20 mg, Oral
House standard
Anticoagulant
(ATC Classification: B01AF01)
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville, Quebec
J7C 3V4
www.labriva.com
Submission Control Number: 276851
Date of Initial Authorization:
AUG
25, 2023
_RIVA RIVAROXABAN (rivaroxaban) _
_ _
_Page 2 of 111_
RECENT MAJOR LABEL CHANGES
N/A
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
5
2
CONTRAINDICATIONS
.................................................................................................
5
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
..............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
......................................................... 7
4.4
Administration
........................................................................................................
11
4.5
Missed Dose
..............................................................................